A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/39110

Title:	A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)
Authors:	Schuler, M. H. H. CUPPENS, Kristof Ploenes, T. Vanbockrijck, M. Wiesweg, M. Darwiche, K. Schramm, A. MAES, Brigitte Hegedus, B. Schildhaus, H-U. Hautzel, H. Theegarten, D. Baas, P. Hartemink, K. Du Pont, B. Aigner, C.
Issue Date:	2022
Publisher:	ELSEVIER
Source:	ANNALS OF ONCOLOGY, 33 (7) , p. S1404
Abstract:	Background: Preoperative immune checkpoint inhibitor therapy (PICIT) is a promising approach in curative treatment of non-small-cell lung cancer (NSCLC). This study explores the feasibility and efficacy of targeting PD-1 and LAG-3 prior to resection.
Document URI:	http://hdl.handle.net/1942/39110
ISSN:	0923-7534
e-ISSN:	1569-8041
DOI:	10.1016/j.annonc.2022.08.034
ISI #:	000866211602444
Category:	M
Type:	Journal Contribution
Appears in Collections:	Research publications

File	Description	Size	Format
LBA37 A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung).pdf Restricted Access	Published version	85.97 kB	Adobe PDF	View/Open Request a copy

12

checked on Sep 2, 2025

Check